Kynurenine pathway in psychosis: Evidence of increased tryptophan degradation

Journal of Psychopharmacology

Volumn 23, Issue 3, 2009, Pages 287-294

  Barry, S ^a   Clarke, G ^a   Scully, P ^a   Dinan, T G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Tryptophan; kynurenine; psychosis

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MOOD STABILIZER; NEUROLEPTIC AGENT; TRYPTOPHAN;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; SYMPTOM; UPREGULATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KYNURENINE; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TRYPTOPHAN; UP-REGULATION;

EID: 65349115896     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089583     Document Type: Article

References (50)

1. Addington D, Addington J, Maticka-Tyndale E, (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry (Suppl. 22). 39 - 44.
2. Allegri G, Costa CVL, Bertazzo A, Biasiolo M, Ragazzi E, (2003) Enyme activities of tryptophan metabolim along the kynurenine pathway in various species of animals. Farmaco 58: 829 - 836. (Pubitemid 37122654)
3. Andreasen NC, (1983) The Scale for the Assessment of Negative Symptoms (SANS), third ed. Rev. ed. Iowa City, IA: University of Iowa.
4. Andreasen NC, (1984) The Scale for the Assessment of Positive Symptoms (SAPS), third ed. Rev. ed. Iowa City, IA: University of Iowa.
5. Avgustin B, Wraber B, Tavcar R, (2005) Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46: 268 - 274.
6. Badawy AA, Evans M, (1976) The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate). Biochem J 156: 381 - 390.
7. Bodaghi B, Goureau O, Zipeto D, Laurent L, Virelizier JL, Michelson S, (1999) Role of IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxidase synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J Immunol 162: 957 - 964. (Pubitemid 29035421)
8. Borroni GC, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R, (2006) Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 113: 1355 - 1365. (Pubitemid 44435873)
9. Byrne GI, Lehmann LK, Kirschbaum JG, Borden EC, Lee CM, Brown RR, (1986) Induction of tryptophan degradation in vitro and in vivo: a gamma interferon stimulated activity. J Interferon Res 6: 389 - 396.
10. Erhardt S, Schwieler L, Engberg G, (2003) Kynurenic acid and schizophrenia. Adv Exp Med Biol 527: 155 - 165. (Pubitemid 38197640)
11. First MB, Spitzer RL, Gibbon M, Williams JBW, (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute.
12. Forrest CM, Youd P, Kennedy A, Gould SR, Darlington LG, Stone TW, (2002) Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci 9: 436 - 442.
13. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB, (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196: 459 - 468.
14. Fuki S, Schwarcz R, Rapoport SI, Takada Y, Smith QR, (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007 - 2017.
15. Gal EM, Sherman AD, (1980) L-kynurenine: its synthesis and possible regulatory function in the brain. Neurochem Res 5: 223 - 239.
16. Golightly KL, Lioyd JA, Hobson JE, Gallagher P, Mercer G, Young AH, (2001) Acute tryptophan depletion in schizophrenia. Psychol Med 3191: 75 - 84. (Pubitemid 32046738)
17. Grant RS, Naf H, Espinosa M, Kapoor V, (2000) IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 5: 101 - 104.
18. Grant RS, Naif H, Thuruthyil SJ, Nsar N, Littlejohn T, Takikawa O, Kapoor V, (2000) Induction of indoleamine 2,3-dioxygenase in primary human macrophages by HIV-1. Redox Rep 5: 105 - 107.
19. Hayashi O, (1980) Biochemical and Medical Aspects of Tryptophan Metabolism. Amsterdam: Elsevier/North-Holland Biomedical Press.
20. Herve C, Beyne P, Jamault H, Delacoux E, (1996) Determination of tryptophan and it?s kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Sci Appl 675: 157 - 161.
21. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP, (1996) Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J 320: 595 - 597.
22. Heyes MP, Chen CY, Major EO, Saito K, (1997) Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 326: 351 - 356.
23. Heyes MP, Morrison PF, (1997) Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J Neurochem 68: 280 - 288. (Pubitemid 26427318)
24. Joseph MH, Baker HF, Crow TJ, Riley GJ, Risby D, (1979) Brain tryptophan metabolism in schizphrenia: a postmortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 62: 279 - 285. (Pubitemid 9229676)
25. Kilzieh N, Wood AE, Erdmann J, Raskind M, Tapp A, (2003) Depression in Kraepelinian schizophrenia. Compr Psychiatry 44: 1 - 6. (Pubitemid 36056767)
26. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B, (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 370 - 382.
27. King NJC, Thomas SR, (2007) Molecules in Focus: Indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 39: 2167 - 2172.
28. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J, (1993) Depression in first episode schizophrenia. Am J Psychiatry 150: 1643 - 1648.
29. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R, (1996) Nicotinic receptor function in schizophrenia. Schizophr Bull 22: 431 - 445. (Pubitemid 26295346)
30. Lodge D, Anis NA, (1982) Effect of phencyclidine on excitatory amino activation of spinal interneurones in the cat. Eur J Phramacol 77: 203 - 204.
31. Magni G, Amici A, Emanuelli M, Raffaelli N, (1999) Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol 73: 135 - 182.
32. Miller CL, Lienos IC, Dulay JR, Weis S, (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074: 25 - 37.
33. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S, (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15: 616 - 629. (Pubitemid 38429977)
34. Moroni F, (1999) Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 375: 87 - 100. (Pubitemid 29317595)
35. Muller N, Riedel M, Ackenheil M, Schwarz MJ, (1999) The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249: 62 - 68.
36. Muller N, Schwarz M, (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurtransmission. Neurotox Res 10: 131 - 148.
37. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch HWM, Leonard BE, (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98: 143 - 151.
38. Rothermundt M, Arolt V, Bayer TA, (2001) Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15: 319 - 339.
39. Saito K, Crowley JS, Markey SP, Heyes MP, (1993) A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268: 15496 - 15503.
40. Sanni LA, Thomas SR, Tattam BN, Moore DE, Chaudhri G, Stocker R, Hunt NH, (1998) Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am J Pathol 152: 611 - 619. (Pubitemid 28106408)
41. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D, (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364: 82 - 90.
42. Schwarcz R, Pellicciari R, (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303: 1 - 10.
43. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC, (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50: 521 - 530. (Pubitemid 32971883)
44. Schwarcz R, Whetsell WO, Mangano RM, (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat-brain. Science 219: 316 - 318. (Pubitemid 13222319)
45. Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM, (1997) Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology 35: 5 - 10.
46. Shepard PD, Joy B, Clerkin L, Schwarz R, (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory gating in the rat. Neuropsychopharmacology 28: 1454 - 1462. (Pubitemid 41070880)
47. Stone TW, (1993) Neuropharmacolgy of quinolinic acid and kynurenic acids. Pharmacol Rev 45: 309 - 379.
48. Stone TW, (2001) Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs 10: 633 - 645.
49. Taylor MW, Feng GC, (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5: 2516 - 2522.
50. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D, (2000) Tryptophan degradation and immune activation in Alzheimer?s disease. J Neural Transm 107: 343 - 353.